+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Lipoprotein-associated phospholipase A2: a new biomarker for cardiovascular risk assessment and potential therapeutic target

Lipoprotein-associated phospholipase A2: a new biomarker for cardiovascular risk assessment and potential therapeutic target

Expert Review of Molecular Diagnostics 7(5): 511-517

Lipoprotein-associated phospholipase (Lp-PL)A2 is a recently described and potentially useful plasma biomarker associated with cardiovascular disease. The enzyme, originally named platelet-activating factor acetylhydrolase (PAF-AH), has two prominent biological activities. First, it inactivates the prominent proinflammatory mediator PAF-AH. Second, Lp-PLA2 hydrolyzes oxidatively modified polyunsaturated fatty acids producing lysophosphatidylcholine (LysoPC) and oxidized nonesterified fatty acids (OxNEFA). OxNEFA have potent monocyte chemotactic activity and LysoPC upregulates inflammatory mediators, including cytokines, adhesion molecules and the chemotactic mediator MCP-1. Whereas the first activity may be considered antiatherogenic, the prevailing consensus is that Lp-PLA2 is positively associated with coronary disease. Initial evidence for this came largely from the West of Scotland Coronary Prevention Study Group (WOSCOPS) in which Lp-PLA2 was compared among 580 cases and 1160 age-matched controls. In addition, the quantitative contribution of Lp-PLA2 to risk assessment was assessed in a substudy of the Atherosclerosis Risk in Communities (ARIC) study. Although positively correlated with disease, the addition of Lp-PLA2 did not appreciably enhance risk prediction beyond the model employing traditional risk factors. Thus, population screening for subclinical disease using Lp-PLA2 does not appear to be warranted. Presently, the most useful application of Lp-PLA2 testing is to adjust individual risk assessment for those patients found to be at borderline risk using traditional models. In this regard, the marker appears to be particularly useful for gauging risk among patients with metabolic syndrome or diabetes. There is observational evidence that Lp-PLA2 may be a useful guide for therapeutic efficacy, but prospective evaluation will be required. Considering the large number of biomarkers currently under evaluation, it is probable that useful additions to existing risk models may be found in combinatorial models.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 054139435

Download citation: RISBibTeXText

PMID: 17892360

DOI: 10.1586/14737159.7.5.511

Related references

Lipoprotein-associated phospholipase A2: a novel marker of cardiovascular risk and potential therapeutic target. Expert Opinion on Investigational Drugs 14(6): 671-679, 2005

Lipoprotein-associated phospholipase A2: a cardiovascular risk predictor and a potential therapeutic target. Future Cardiology 5(2): 159-173, 2009

Lipoprotein-associated phospholipase A2: how effective as a risk marker of cardiovascular disease and as a therapeutic target?. Inflammation and Allergy Drug Targets 10(4): 236-246, 2011

Lipoprotein-associated phospholipase A2: a potential new risk factor for coronary artery disease and a therapeutic target. Current Opinion in Pharmacology 1(2): 121-125, 2001

Lipoprotein Associated Phospholipase A2 Assessment of a new assay for potential use as a marker of cardiovascular risk. Clinical Chemistry 48(6 Suppl.): A105, 2002

Lipoprotein-associated phospholipase A2 as a biomarker of coronary heart disease and a therapeutic target. Current Opinion in Cardiology 24(4): 358-363, 2009

Scavenger receptor Class B type I as a potential risk stratification biomarker and therapeutic target in cardiovascular disease. Journal of Cellular Physiology 234(10): 16925-16932, 2019

Lipoprotein-associated phospholipase A2 (Lp-PLA(2)): a novel and promising biomarker for cardiovascular risks assessment. Disease Markers 34(5): 323-331, 2013

Lipoprotein associated phospholipase A(2): role in atherosclerosis and utility as a biomarker for cardiovascular risk. Epma Journal 2(1): 27-38, 2011

Lipoprotein-associated phospholipase A2: a potential therapeutic target for atherosclerosis. Current Drug Targets. Cardiovascular and Haematological Disorders 5(6): 527-532, 2005

Lipoprotein-associated Phospholipase A2: A Potential Therapeutic Target for Atherosclerosis. Current Drug Targets - Cardiovascular and Haematological Disorders 5(6): 527-532, 2005

Role of lipoprotein-associated phospholipase A2 in atherosclerosis and its potential as a therapeutic target. Current Opinion in Pharmacology 6(2): 154-161, 2006

STABILITY and SOLID-TIMI 52: Lipoprotein associated phospholipase A2 (Lp-PLA2) as a biomarker or risk factor for cardiovascular diseases. Global Cardiology Science and Practice 2015: 6, 2015

Clinical review: Lipoprotein-associated phospholipase A2, a novel inflammatory biomarker and independent risk predictor for cardiovascular disease. Journal of Clinical Endocrinology and Metabolism 90(5): 3100-3105, 2005

The role of lipoprotein-associated phospholipase a₂ as a marker and potential therapeutic target in atherosclerosis. Current Atherosclerosis Reports 13(2): 132-137, 2011